Skip to content Skip to footer

News

Preliminary Analysis of Real-Time Therapy-Based Interventions with ID-Cap™ System Demonstrates Effectiveness of Maintaining Adherence for High-Risk Populations

Preliminary Analysis of Real-Time Therapy-Based Interventions with ID-Cap™ System Demonstrates Effectiveness of Maintaining Adherence for High-Risk Populations

8/28/2023

NCT03512418- An ongoing study designed to evaluate PrEP adherence data using cognitive behavioral therapy based interventions delivered through the ID-Cap™ System in MSM (men who...

Read More
Placeholder

High Patient Engagement with the ID-Cap™ System on 98.0% of Use-Days in a Clinical Study During the COVID-19 Pandemic

3/24/2023

COVID-19 caused many interruptions in clinical trials. After a brief pause in external clinical research, clinical studies involving use of the FDA-cleared ID-Cap System from...

Read More
Placeholder

Remote Therapy Monitoring Billing Guide

3/24/2023

In 2022 the Centers for Medicare and Medicaid Services (CMS) expanded its digital health coverage and began reimbursing providers for remote therapy monitoring (RTM). RTM...

Read More
Placeholder

Leading Digital Pill Solution Surpasses 10,000 Ingestions

3/24/2023

etectRx™, Inc. (etectRx™), the standard in FDA-cleared digital medication adherence, today announced that its digital pill, the ID-Cap System has surpassed 10,000 ingestions, a significant...

Read More
Placeholder

Formative Acceptance of Ingestible Biosensors to Measure Adherence to TB Medications

9/28/2022

Tuberculosis (TB) represents a significant public health threat in India. Adherence to antitubercular therapy (ATT) is the key to reducing the burden of this infectious...

Read More
Placeholder

AARDEX® Group Adds etectRx to their MEMS® Adherence Hardware Ecosystem

4/29/2022

The partnership sees the integration of AARDEX’s adherence analytics software with etectRx’s ingestible adherence sensor Liege, Belgium (APRIL 28th, 2022) – Belgium-based AARDEX® Group, the...

Read More
Placeholder

Development of a Digital Pill and Respondent Behavioral Intervention (PrEPSteps) for HIV Pre-exposure Prophylaxis Adherence Among Stimulant Using Men Who Have Sex With Men

9/7/2021

Our ID-Cap™ System was recently utilized in a clinical study in Boston, MA resulting in a research report drafted by Principal Investigator Dr. Peter Chai...

Read More
Placeholder

The Case for Digital Pill Use in Clinical Trials

8/17/2021

Those who design and run clinical trials often worry about medication adherence among trial participants. Nonadherence is a significant concern in all types of clinical...

Read More
Placeholder

etectRx Announces Eric Buffkin as New CEO

7/30/2021

Company Founder Takes the Helm of etectRx, a Digital Health Company GAINESVILLE, Fla. (August 2, 2021) – etectRx™, Inc. (etectRx™), a privately held digital health...

Read More
Placeholder

etectRx Announces Launch of MyTPill Study to Address Medication Adherence Among HIV+ Prescription Opioid Users

5/4/2021

GAINESVILLE, Fla. & BOSTON, Mass. (May 4, 2021) – Digital health company, etectRx, Inc., today announced the launch of a study to monitor antiretroviral therapy...

Read More
Placeholder

WHITEPAPER: The Extraordinary Problem of Medication Nonadherence in Oncology Patients And How Digital Pills Can Make a Difference

5/4/2021

Cancer is often highly treatable due to new therapies, especially oral agents, that have improved outcomes and survival rates, and allow patients to be treated...

Read More
Placeholder

etectRx “It Already Does That”

4/30/2021

Inspiration struck the etectRx team after watching the Apple Watch Series 6 – “It Already Does That” campaign. etectRx enthusiastically created its version of “It...

Read More